Palvella Therapeutics, Inc.PVLA
Price (close)
$146.07
Market cap
$2.1B
P/E
—
Revenue (TTM)
—
Net income
-$61.7M
Dividend yield
—
1-year total return
153.2%
Net margin
—
Revenue growth
—
Debt / equity
—
What Palvella Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $29.3M | $31.4M | $25.9M | $42.8M | — | — |
| Net income | -$37.2M | -$45.7M | -$33.3M | $18.7M | -$17.4M | -$41.7M |
| Free cash flow | -$48.6M | -$8.6M | -$61.0M | -$13.9M | — | — |
More on PVLA.
- Palvella Therapeutics, Inc. summary
- Palvella Therapeutics, Inc. financial statements
- Palvella Therapeutics, Inc. key metrics
- Palvella Therapeutics, Inc. health scores and style box
- Palvella Therapeutics, Inc. earnings
- Palvella Therapeutics, Inc. dividends
- Palvella Therapeutics, Inc. valuation
- Palvella Therapeutics, Inc. ownership and insiders
- Palvella Therapeutics, Inc. peers
Figures from Palvella Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.